Ohgun Kwon

(1)

Ohgun Kwon

¹

, Young Uh

^1,2

, Gyu Yul Hwang

¹

, An Sook Jung

¹

, and Kap Jun Yoon

¹

(2)

(3)

†

‡

*

†

‡

†

‡

†

‡

* † ‡

(4)

‡ ¶

† ∮

†

*

†

‡

†

∥

‡ ∥

‡

†

† ¶

‡

* † ‡ ∮ ∥ ¶

(5)

*∥**∥* †∥†‡∥∮ *†‡ ∮∥ * *†*† †‡ *†‡

(6)

** † † †† *†

(7)

*† *∮ * † †‡∮

(8)

** † † † † *†

(9)

(10)

(11)

1. Rodan GA and Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.

2. Chien KR and Karsenty G. Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell 2005;120:533-44.

3. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation.

Cell 2005;122:803-15.

4. Riggs BL and Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986;314:1676-86.

5. Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, DiMunno O, et al. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 2008;82:341-7.

6. Ebeling PR and Akesson K. Role of biochemical markers in the management of osteoporosis. Best Pract Res Clin Rheumatol 2001;15:385-400.

7. , , , , , . Elecsys

2010 CTX Osteocalcin .

2001;21:459-64.

8. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-69.

9. Hadjidakis DJ and Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006;1092:385-96.

10. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006;91:2882-7.

11. Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008;45:221-58.

12. , , , . Elecsys 2010

. 2006;26:

146-52.

13. , , , , , .

osteocalcin deoxypyridonoline

. 1997;17:245-51.

14. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.

World Health Organ Tech Rep Ser 1994;843:1-129.

15. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996312:1254-9.

16. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE,et al. Bone mineral density thresholds for pharmacologic intervention to prevent fractures. Arch Intern Med 2004;164:1108-12.

17. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, et al.Factors associated with 5-year risk of hip fracture in postmenopausal women.

JAMA 2007;298:2389-98.

18. Miller PD, Baran DT, Bilezikian JP, Greenspan SL,Lindsay R, Riggs BL, et al. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom 1999;2:323-42.

19. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 2007;92:443-9.

20. Szulc P, Kaufman JM, Delmas PD. Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 2007;18:1451-61.

21. Filip RS and Zagórski J. Age- and BMD-related differences in biochemical markers of bone metabolism in rural and urban women from Lublin Region, Poland. Ann Agric Environ Med 2004;11:255-9.

22. Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y, et al. Reference database of biochemical markers of bone turnover for the Japanese female population.

Japanese Population-based Osteoporosis (JPOS) Study.

Osteoporos Int 2004;15:981-91.

23. Weinbrenner T, Zittermann A, Gouni-Berthold I, Stehle P, Berthold HK. Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study. Eur J Clin Nutr 2003;57:1262-7.

24. Caillot-Augusseau A, Lafage-Proust MH, Soler C, Pernod J, Dubois F, Alexandre C. Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95). Clin Chem 1998;44:578-85.

25. de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz

A, Chen E, et al. A cross-sectional study of bone turnover

markers in healthy premenopausal women. Bone

2007;40:1222-30.

(12)

26. Greendale GA, Lee NP, Arriola ER. Lancet. The menopause. 1999;353:571-80.

27. Lukacs JL and Reame NE. Concentrations of follicle-stimulating hormone correlate with alkaline phosphatase and a marker for vitamin K status in the perimenopause. J Womens Health Gend Based Med 2000;9:731-9.

28. Iwamoto J, Takeda T, Ichimura S. Combined treatment with vitamin K2 and bisphosphonate in postmenopausal women

with osteoporosis. Yonsei Med J 2003;44:751-6.

29. Gundberg CM, Looker AC, Nieman SD, Calvo MS. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone 2002;31:703-8.

Ohgun Kwon

Ohgun Kwon

, Young Uh

, Gyu Yul Hwang

, An Sook Jung

, and Kap Jun Yoon

1. Rodan GA and Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.

2. Chien KR and Karsenty G. Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell 2005;120:533-44.

3. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation.

Cell 2005;122:803-15.

4. Riggs BL and Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986;314:1676-86.

5. Adami S, Bianchi G, Brandi ML, Giannini S, Ortolani S, DiMunno O, et al. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 2008;82:341-7.

6. Ebeling PR and Akesson K. Role of biochemical markers in the management of osteoporosis. Best Pract Res Clin Rheumatol 2001;15:385-400.

7. , , , , , . Elecsys

2010 CTX Osteocalcin .

2001;21:459-64.

8. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-69.

9. Hadjidakis DJ and Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006;1092:385-96.

10. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006;91:2882-7.

11. Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008;45:221-58.

12. , , , . Elecsys 2010

. 2006;26:

146-52.

13. , , , , , .

osteocalcin deoxypyridonoline

. 1997;17:245-51.

14. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.

World Health Organ Tech Rep Ser 1994;843:1-129.

15. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996312:1254-9.

16. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE,et al. Bone mineral density thresholds for pharmacologic intervention to prevent fractures. Arch Intern Med 2004;164:1108-12.

17. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, et al.Factors associated with 5-year risk of hip fracture in postmenopausal women.

JAMA 2007;298:2389-98.

18. Miller PD, Baran DT, Bilezikian JP, Greenspan SL,Lindsay R, Riggs BL, et al. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom 1999;2:323-42.

19. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 2007;92:443-9.

20. Szulc P, Kaufman JM, Delmas PD. Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 2007;18:1451-61.

21. Filip RS and Zagórski J. Age- and BMD-related differences in biochemical markers of bone metabolism in rural and urban women from Lublin Region, Poland. Ann Agric Environ Med 2004;11:255-9.

22. Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y, et al. Reference database of biochemical markers of bone turnover for the Japanese female population.

Japanese Population-based Osteoporosis (JPOS) Study.

Osteoporos Int 2004;15:981-91.

23. Weinbrenner T, Zittermann A, Gouni-Berthold I, Stehle P, Berthold HK. Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study. Eur J Clin Nutr 2003;57:1262-7.

24. Caillot-Augusseau A, Lafage-Proust MH, Soler C, Pernod J, Dubois F, Alexandre C. Bone formation and resorption biological markers in cosmonauts during and after a 180-day space flight (Euromir 95). Clin Chem 1998;44:578-85.

25. de Papp AE, Bone HG, Caulfield MP, Kagan R, Buinewicz

A, Chen E, et al. A cross-sectional study of bone turnover

markers in healthy premenopausal women. Bone

2007;40:1222-30.

26. Greendale GA, Lee NP, Arriola ER. Lancet. The menopause. 1999;353:571-80.

27. Lukacs JL and Reame NE. Concentrations of follicle-stimulating hormone correlate with alkaline phosphatase and a marker for vitamin K status in the perimenopause. J Womens Health Gend Based Med 2000;9:731-9.

28. Iwamoto J, Takeda T, Ichimura S. Combined treatment with vitamin K2 and bisphosphonate in postmenopausal women

with osteoporosis. Yonsei Med J 2003;44:751-6.

29. Gundberg CM, Looker AC, Nieman SD, Calvo MS. Patterns of osteocalcin and bone specific alkaline phosphatase by age, gender, and race or ethnicity. Bone 2002;31:703-8.

30. Szulc P, Montella A, Delmas PD. High bone turnover is

associated with accelerated bone loss but not with increased

fracture risk in men aged 50 and over: the prospective

MINOS study. Ann Rheum Dis 2008;67:1249-55.